Sana Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 04:24 pm EST
Share
Sana Biotechnology, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net income was USD 0.984 million compared to net loss of USD 85.12 million a year ago.
For the nine months, net loss was USD 195.14 million compared to USD 189.03 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 1.01 a year ago. Diluted loss per share from continuing operations was USD 1.01 compared to USD 1.01 a year ago.
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.
SANA BIOTECHNOLOGY, INC. 
